PE20040265A1 - Compuestos de quinazolina utiles en terapia - Google Patents

Compuestos de quinazolina utiles en terapia

Info

Publication number
PE20040265A1
PE20040265A1 PE2003000247A PE2003000247A PE20040265A1 PE 20040265 A1 PE20040265 A1 PE 20040265A1 PE 2003000247 A PE2003000247 A PE 2003000247A PE 2003000247 A PE2003000247 A PE 2003000247A PE 20040265 A1 PE20040265 A1 PE 20040265A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
het4
het3
het2
Prior art date
Application number
PE2003000247A
Other languages
English (en)
Inventor
Julian Blagg
Michael Jonathan Fray
Alan Stobie
John Paul Mathias
Mark Henryk Stefaniak
Mark Llewellyn Lewis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20040265A1 publication Critical patent/PE20040265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINAZOLINA DE FORMULA (I) DONDE R1 ES ALQUILO C1-C4; R2 ES HALO, ALQUILO C1-C4, CICLOALQUILO C3-C6, CICLOALQUILOXI C3-C6, -SO2(ALQUILO C1-C4), ALQUILOXI C1-C4, Het O -OHet; R3 ES UN BICICLICO DE FORMULA (II) DONDE X E Y ES C Y N, O AL MENOS UNO SEA C Y EL ANILLO A JUNTO CON X E Y ES UN ANILLO AROMATICO DE 5 O 6 MIEMBROS QUE CONTIENE 0, 1, 2 O 3 NITROGENOS; L ES ALQUILENO C1-C4 O ALCOXIALQUILENO C1-C4; R4 ES H, -NR5R6, CICLOALQUILO C3-C6, -OR7, Het1 O Het4; R5 Y R6 ES H, CICLOALQUILO C3-C6, CICLOALQUIL C3-C6-ALQUILENO C1-C4, -SO2(ALQUILO C1-C4) Y ALQUILO; R7 ES H, ALQUILO C1-C4, ALCOXIALQUILO C1-C4, CICLOALQUILO C3-C6, Het2 Y ALQUILC1-C4-Het3; R8 ES H O ALQUILO; Het, Het1, Het2 Y Het3 ES UN HETEROCICLICO SATURADO DE 4 A 7 MIEMBROS, MONO O BICICLICO CON HETEROATOMOS DE N, O O S; Het4 ES UN HETEROCICLICO DE 5 A 6 MIEMBROS; R9 ES H O ALQUILO C1-C4; R10 Y R11 ES H, ALQUILO C1-C4.SON COMPUESTOS PREFERIDOS 5-CICLOPROPIL-7-METOXI-2-(2-([DIMETILAMINO]METIL)-7,8-DIHIDRO[1,6]NAFTIRIDIN-6(5H)-IL)-4(3H)-QUINAZOLINONA; 5-CICLOPROPIL-7-METOXI-2-(2-(1-PIRROLIDINILMETIL)-7,8-DIHIDRO[1,6] NAFTIRIDIN-6(5H)-IL)-4(3H)-QUINAZOLINONA, ENTRE OTROS.TAMBIEN SE REFIERE A UN METODO DE PREPARACION. SON ANTAGONISTAS SELECTIVOS DE SUBTIPOS DE RECEPTORES PROSTATICO DE and-ADRENORECEPTORES.SON UTILES EN EL TRATAMIENTO DE LA HIPERTENSION, INFARTO DE MIOCARDIO, DISFUNCION ERECTIL MASULINA, HIPERLIPEDEMIA, ARRITMIA CARDIACA, GLAUCOMA E HIPERPLASIA PROSTATICA BENIGNA
PE2003000247A 2002-03-14 2003-03-11 Compuestos de quinazolina utiles en terapia PE20040265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0206033.3A GB0206033D0 (en) 2002-03-14 2002-03-14 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
PE20040265A1 true PE20040265A1 (es) 2004-05-01

Family

ID=9932974

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000247A PE20040265A1 (es) 2002-03-14 2003-03-11 Compuestos de quinazolina utiles en terapia

Country Status (19)

Country Link
US (1) US6936619B2 (es)
EP (1) EP1483257B1 (es)
JP (1) JP2005532275A (es)
AR (1) AR038949A1 (es)
AT (1) ATE339414T1 (es)
AU (1) AU2003209594A1 (es)
BR (1) BR0308407A (es)
CA (1) CA2479016A1 (es)
DE (1) DE60308332T2 (es)
ES (1) ES2271618T3 (es)
GB (1) GB0206033D0 (es)
GT (1) GT200300059A (es)
HN (1) HN2003000100A (es)
MX (1) MXPA04008939A (es)
PA (1) PA8569501A1 (es)
PE (1) PE20040265A1 (es)
TW (1) TW200305420A (es)
UY (1) UY27711A1 (es)
WO (1) WO2003076427A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
DE60307483T2 (de) 2002-08-07 2007-07-05 Novartis Ag Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
US20040132728A1 (en) * 2002-09-17 2004-07-08 Pfizer Inc Combinations of atorvastatin and alpha1adrenergic receptor antagonists
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
JP2009513504A (ja) * 2003-07-02 2009-04-02 エフ．ホフマン−ラ ロシュ アーゲー ５−置換キナゾリノン誘導体
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP5396379B2 (ja) 2007-04-02 2014-01-22 エボテック・アーゲー ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
ES2439255T3 (es) 2007-06-21 2014-01-22 Cara Therapeutics, Inc. Imidazoheterociclos sustituidos
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US8586733B2 (en) 2008-07-31 2013-11-19 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
WO2011022213A1 (en) * 2009-08-17 2011-02-24 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine pde10 inhibitors
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
KR20150041040A (ko) 2012-08-06 2015-04-15 세노믹스, 인코포레이티드 단맛 향미 개질제
PL2906531T3 (pl) * 2012-10-15 2018-04-30 Resverlogix Corp. Związki użyteczne w syntezie związków benzamidowych
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
KR20160095157A (ko) * 2013-12-20 2016-08-10 레이보러토리오스델디알에스티브에스에이 융합 이미다졸릴 유도체, 그의 제조 방법 및 의약으로서의 용도
HUE039262T2 (hu) * 2014-05-28 2018-12-28 Hoffmann La Roche 5-oxa-2-azabiciklo [2.2.2] oktán-4-il- és 5-oxa-2-azabiciklo [2.2.1] heptán-4-il-származékok TAAR1 modulátorokként
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法
DK3889145T3 (da) 2015-12-17 2024-03-18 Merck Patent Gmbh 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
US10730830B2 (en) 2016-01-29 2020-08-04 Ono Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative
EP4198031A1 (en) * 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
US11945813B2 (en) 2018-08-07 2024-04-02 Firmenich Incorporated 5-substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085213A (en) * 1976-01-28 1978-04-18 Pfizer Inc. Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
MXPA03005854A (es) * 2001-01-02 2003-09-10 Hoffmann La Roche Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b.

Also Published As

Publication number Publication date
PA8569501A1 (es) 2003-12-10
UY27711A1 (es) 2003-10-31
DE60308332T2 (de) 2007-01-11
MXPA04008939A (es) 2004-11-26
TW200305420A (en) 2003-11-01
EP1483257A1 (en) 2004-12-08
DE60308332D1 (de) 2006-10-26
WO2003076427A8 (en) 2004-10-07
AR038949A1 (es) 2005-02-02
HN2003000100A (es) 2003-12-15
CA2479016A1 (en) 2003-09-18
ES2271618T3 (es) 2007-04-16
GT200300059A (es) 2003-10-15
BR0308407A (pt) 2005-01-11
US20040029859A1 (en) 2004-02-12
ATE339414T1 (de) 2006-10-15
AU2003209594A1 (en) 2003-09-22
WO2003076427A1 (en) 2003-09-18
GB0206033D0 (en) 2002-04-24
US6936619B2 (en) 2005-08-30
JP2005532275A (ja) 2005-10-27
EP1483257B1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
PE20040265A1 (es) Compuestos de quinazolina utiles en terapia
PE20010736A1 (es) PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
PE20051141A1 (es) Inhibidores de la polimerasa viral
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20011068A1 (es) 1,3-pirrolidinas disustituidas
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
PE20060299A1 (es) DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA
AR056821A1 (es) Derivados de piperidina sustituida por heteroarilo
YU63500A (sh) Pirazolopirimidinon cgmp pde5 inhibitori za tretman seksualne disfunkcije
PE20030415A1 (es) Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt
AR065300A1 (es) Compuestos quimicos derivados de 1,2-pirazol
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20061351A1 (es) COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
HK1108882A1 (en) Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
PE20061354A1 (es) Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv
PE68699A1 (es) Pirazolopirimidonas para disfuncion sexual
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
PE20080608A1 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed